News

June 16, 2013

CTI Announces New Data Presented at EHA 2013 Congress Demonstrating the Safety and Tolerability Profile of Pacritinib in Patients with Myelofibrosis

June 16, 2013

New EXTEND Analyses Evaluate Efficacy of Single Agent PIXUVRIŽ in 3rd and 4th Line Salvage Setting With and Without Prior Rituximab Treatment

view all news releases

Events

 No events scheduled

view all events

Pixuvri® Approved in E.U.

PIXUVRI is the only medicine approved as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-Cell lymphomas in the E.U.

Download Summary of Product Characteristics and Package Insert

Pixantrone is marketed in the E.U. as PIXUVRI | Learn more

Resources

patient & caregiver information medical professionals information

Pipeline

Our late-stage development pipeline addresses a full complement of blood-related cancers.

learn about our oncology pipeline

Video Highlights

Our Mission
 

James Bianco, M.D., President and CEO, explains CTI's mission to develop less toxic and more effective therapies for people living with cancer.
 

You are now leaving website and entering the website.

If you would like to continue, click Continue.

CancelContinue